Ivonib, a targeted drug specifically designed to treat IDH1 mutated acute myeloid leukemia

Ivosidenib (Ivosidenib) is a targeted drug specially developed to treat a specific type of acute myeloid leukemia (AML). AML This malignant blood cancer mainly attacks hematopoietic stem cells in the bone marrow and blood, causing abnormal white blood cells to surge and the disease progresses rapidly, posing a serious threat to the patient's health. What is unique about ivosidenib is that it precisely targets AML patients with IDH1 (isocitrate dehydrogenase 1) gene mutations.

According to statistics, about 6-10% of AML patients carry IDH1 gene mutations. This mutation causes the abnormal accumulation of the metabolite 2-hydroxyglutarate (2-HG), interferes with normal hematopoiesis, and accelerates the development of AML. By inhibiting the activity of mutated IDH1 enzyme, reducing the production of 2-HG and restoring normal cell differentiation and maturation, ivonib brings significant therapeutic effects to patients with mutated IDH1 AML.

Ivonib is commonly used to treat patients with IDH1 mutationsAML who are relapsed or refractory to premenstrual therapy. For this group of patients, traditional chemotherapy has limited effects, while ivonib provides a new treatment option that can effectively delay disease progression and improve survival rates. Clinical trials have shown that ivonib has a good response rate, and some patients can achieve long-term complete remission.

In addition, ivonib's potential in other cancers is also being studied, such as solid tumors such as cholangiocarcinoma. However, its main indication at present is still IDH1mutated AML. It should be noted that ivonib is only suitable for patients with IDH1 mutations, and genetic testing is required before treatment. This personalized treatment highlights the important role of targeted drugs in modern cancer treatment.